146 related articles for article (PubMed ID: 38765300)
1. Association Between Disease-Modifying Therapy and Information Processing Speed in Multiple Sclerosis.
Aboseif A; Amin M; Bena J; Nakamura K; Macaron G; Ontaneda D
Int J MS Care; 2024; 26(3):91-97. PubMed ID: 38765300
[TBL] [Abstract][Full Text] [Related]
2. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
[TBL] [Abstract][Full Text] [Related]
3. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
4. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
5. The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis.
Labiano-Fontcuberta A; Costa-Frossard L; Sainz de la Maza S; Rodríguez-Jorge F; Chico-García JL; Monreal E
Mult Scler Relat Disord; 2022 Aug; 64():103959. PubMed ID: 35717900
[TBL] [Abstract][Full Text] [Related]
6. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
8. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Harris H; Conway D; Thompson NR
Mult Scler Relat Disord; 2019 May; 30():252-256. PubMed ID: 30851638
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients.
Abbatemarco JR; Ontaneda D; Nakamura K; Husak S; Wang Z; Alshehri E; Bermel RA; Conway DS
Mult Scler Relat Disord; 2020 Nov; 46():102593. PubMed ID: 33296988
[TBL] [Abstract][Full Text] [Related]
10. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
[TBL] [Abstract][Full Text] [Related]
11. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
12. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
14. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
16. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
17. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
[TBL] [Abstract][Full Text] [Related]
19. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
